Gadoversetamide Levels and Effects while Breastfeeding
Summary of Use during Lactation
There is no published experience with gadoversetamide during breastfeeding. Gadoversetamide releases more free gadolinium than some other gadolinium-containing contrast agents. However, guidelines developed by North American professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1,2] Other agents may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Copel J, El-Sayed Y, Heine RP, et al. Committee Opinion No. 723: Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol. 2017;130:e210–e216. [PubMed: 28937575]
2.
American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2022;Version 2022:106-7. https://www.acr.org/Clinical-Resources/Contrast-Manual.
Substance Identification
Substance Name
Gadoversetamide
CAS Registry Number
131069-91-5
Drug Class
Breast Feeding
Lactation
Milk, Human
Contrast Media
Diagnostic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
